Novartis Q3 net income drops 70% to USD 1.2 billion
NVS•Novartis' third-quarter 2026 net income fell 70% to USD 1.2 billion, while net sales rose to USD 14.52 billion. A USD 1.9 billion partial impairment followed del-desiran missing its Phase III primary endpoint in myotonic dystrophy.
1. Quarterly results
Novartis' third-quarter 2026 net income fell 70% to USD 1.2 billion due to lower operating income and higher interest expense. Net sales rose to USD 14.52 billion, with volume growth partly offset by generic competition.
2. Drug impairment
A USD 1.9 billion partial impairment affected del-desiran after the drug missed its Phase III primary endpoint in myotonic dystrophy.
